|
| 35940477 | Extramacular Drusen and Progression of Age-Related Macular Degeneration: Age Related Eye Disease Study 2 Report 30. | Ophthalmol Retina | 2023 |
| 36728692 | DEFINING "STRONG" VERSUS "WEAK" RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR CENTER-INVOLVED DIABETIC MACULAR EDEMA. | Retina | 2023 |
| 35093585 | Diagnosing Persistent Hypertransmission Defects on En Face OCT Imaging of Age-Related Macular Degeneration. | Ophthalmol Retina | 2022 |
| 35833805 | Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. | N Engl J Med | 2022 |
| 33972701 | Correction: Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study. | Bone Marrow Transplant | 2021 |
| 33686249 | Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study. | Bone Marrow Transplant | 2021 |
| 34967834 | Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments. | Transl Vis Sci Technol | 2021 |
| 34004001 | Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium. | Transl Vis Sci Technol | 2021 |
| 32200813 | Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. | Ophthalmology | 2020 |
| 31899035 | Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40. | Ophthalmology | 2020 |
| 33133772 | The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline. | Transl Vis Sci Technol | 2020 |
| 32446738 | Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity. | Am J Ophthalmol | 2020 |
| 30278196 | Longitudinal Study of Dark Adaptation as a Functional Outcome Measure for Age-Related Macular Degeneration. | Ophthalmology | 2019 |
| 31558345 | Prevalence, Risk, and Genetic Association of Reticular Pseudodrusen in Age-related Macular Degeneration: Age-Related Eye Disease Study 2 Report 21. | Ophthalmology | 2019 |
| 30896764 | Association of Dietary and Supplementary Calcium Intake With Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 39. | JAMA Ophthalmol | 2019 |
| 31019847 | A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned. | Transl Vis Sci Technol | 2019 |
| 30476517 | Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. | Ophthalmology | 2019 |
| 29677357 | Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity. | Invest Ophthalmol Vis Sci | 2018 |
| 30021497 | University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (afternoon panel session). | Clin Trials | 2018 |
| 30043039 | Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. | JAMA Ophthalmol | 2018 |
| 30060980 | Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. | Ophthalmology | 2018 |
| 29776671 | Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. | Ophthalmology | 2018 |
| 29681290 | Public Health Burden and Potential Interventions for Myopia. | Ophthalmology | 2018 |
| 29454660 | Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. | Ophthalmology | 2018 |
| 27154918 | Age-related macular degeneration in patients with uveitis. | Br J Ophthalmol | 2017 |
| 28335957 | Reply. | Ophthalmology | 2017 |
| 28219516 | Reply. | Ophthalmology | 2017 |
| 28492921 | Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy. | JAMA Ophthalmol | 2017 |
| 28180033 | Platform-Independent Cirrus and Spectralis Thickness Measurements in Eyes with Diabetic Macular Edema Using Fully Automated Software. | Transl Vis Sci Technol | 2017 |
| 28702674 | Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases. | Invest Ophthalmol Vis Sci | 2017 |
| 28620652 | Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. | Ophthalmol Retina | 2017 |
| 28602520 | Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation. | Ophthalmology | 2017 |
| 27930768 | Listening to the Patients-The Laser-Assisted In Situ Keratomileusis Quality of Life Collaboration Project. | JAMA Ophthalmol | 2017 |
| 28006042 | Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. | JAMA Ophthalmol | 2017 |
| 27893066 | Symptoms and Satisfaction of Patients in the Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL) Studies. | JAMA Ophthalmol | 2017 |
| 27893063 | Assessment of the Psychometric Properties of a Questionnaire Assessing Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL). | JAMA Ophthalmol | 2017 |
| 27031504 | Quantification of Ellipsoid Zone Changes in Retinitis Pigmentosa Using en Face Spectral Domain-Optical Coherence Tomography. | JAMA Ophthalmol | 2016 |
| 26545319 | Longitudinal Study of Age-Related Cataract Using Dynamic Light Scattering: Loss of α-Crystallin Leads to Nuclear Cataract Development. | Ophthalmology | 2016 |
| 26605836 | Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. | JAMA Ophthalmol | 2016 |
| 27699406 | Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop. | Invest Ophthalmol Vis Sci | 2016 |
| 27450826 | Reply. | Ophthalmology | 2016 |
| 27442263 | Evaluating the Validity of the Age-Related Eye Disease Study Grading Scale for Age-Related Macular Degeneration: AREDS2 Report 10. | JAMA Ophthalmol | 2016 |
| 27549874 | Preventing Diabetic Retinopathy Progression. | Ophthalmology | 2016 |
| 27342325 | Intracameral Antibiotics and Cataract Surgery: Endophthalmitis Rates, Costs, and Stewardship. | Ophthalmology | 2016 |
| 27156698 | Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. | Ophthalmology | 2016 |
| 26746868 | Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. | JAMA Ophthalmol | 2016 |
| 26686966 | The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8. | Ophthalmology | 2016 |
| 26935357 | Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. | Ophthalmology | 2016 |
| 26802783 | Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. | Am J Ophthalmol | 2016 |
| 26875003 | A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema. | Ophthalmology | 2016 |